CClinicalTrials.gg
CompletedNCT02512666Updated Jun 11, 2018

Non Invasive Optical Imaging of WBC Count

An interventional study of AM4113-N5UT Dino-Lite in Hematologic Malignancy, sponsored by Massachusetts General Hospital. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-06-11.

Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Device feasibility

Phase
Not applicable
Study type
Interventional
Enrollment
45
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This research study is looking at a small device that measures white blood cell (WBC) counts by being placed against the finger nail for participants who are undergoing stem cell transplantation at Massachusetts General Hospital or have a hematologic malignancy and are being seen as an outpatient.

Read the detailed description

The objective of this study is to obtain data that would support the use of a method to obtain WBC counts from images of small blood vessels called capillaries. These would be obtained by pressing a small device on the surface of participants' finger nails to look through the nail. These images will be obtained using a portable microscope called the Dino-Lite Digital Microscope.

Having a non-invasive way to quickly measure WBC counts could be useful for a variety of healthcare applications.

02

Conditions studied

  • Hematologic Malignancy

Keywords

  • Hematologic malignancy
03

In context

Neoplasms

9,365 studies on the registry are indexed under Neoplasms; 2,489 are open to participants now.

This study's enrollment of 45 is close to the median of 50 across 7,253 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Massachusetts General Hospital is the lead sponsor of 2,536 studies on the registry; 446 are open to participants now.

Of its 214 completed or terminated interventional studies of FDA-regulated products, 161 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients with lymphoid malignancies or plasma cell dyscrasias who are admitted to the Massachusetts General Hospital to undergo autologous stem cell transplantation or are seen in the outpatient clinic
  • Age ≥ 18 years
  • Ability to understand and the willingness to sign a written informed consent document.
  • Patients must have WBC ≥ 3000 / µl and ANC ≥ 1500 / µl at admission or their last clinical visit to be enrolled.

Exclusion criteria

Exclusion Criteria:

  • History of allergic reactions attributed to compounds of similar chemical or biologic composition of baby oil.
  • Myelodysplasia
  • Skin phototype \< 4 in the Fitzpatrick scale.
05

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    Non-Invasive Imaging

    Commercial portable optical microscope (AM4113-N5UT Dino-Lite ) which will be employed during the study for a pre determined time of non-invasive imaging of the nailfold capillaries in ASCT patients. For Autologous Stem Cell Transplant (ASCT) participants, the imaging will be performed once prior to ASCT upon admission to the hospital, and then daily after ASCT (starting on day +7) until count recovery

    Device: AM4113-N5UT Dino-Lite

Interventions

  • DeviceAM4113-N5UT Dino-Lite
06

What researchers measure

Primary outcomes

  1. Video of nail-fold imaging captured by capillaroscope

    Image acquisition from device to then analyze and compare with complete blood counts measured in a standard fashion

    Time frame: 4 weeks

07

Study locations

1 site
  • Massachusetts General Hospital
    Boston, Massachusetts 02115, United States
08

References and documents

Individual participant data

Plan to share: No — No plan to share data

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 11, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02512666
Lead sponsor
Massachusetts General Hospital
Responsible party
Yi-Bin A. Chen, MD (Principal Investigator, Massachusetts General Hospital) — Principal investigator
First posted
Jul 31, 2015
Start date
Sep 2015
Primary completion
Sep 2017
Completion
Sep 2017
Last update
Jun 11, 2018

Study contacts

Yi-Bin A Chen, MD
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion